CD274 and non-small cell lung carcinoma: In clinical trials under several conditions, PD‐1 and PD‐L1 inhibitors have significantly improved prognostic indicators (OS and PFS) in advanced NSCLC compared with that of conventional anticancer drugs.19, 20, 21, 22